Table 2.
Follow-up time and survival among 708 participants with lung cancer from cohort studies in Europe, North America, Asia, and Australia.
| Overall | EPIC | NSHDS | MCCS | CPS-II | HUNT | SCHS | |
|---|---|---|---|---|---|---|---|
| Number of cases | 708 | 183 | 63 | 105 | 115 | 154 | 88 |
| Median follow-up years (IQR)a | 14.3 (14.0–14.6) | 13.8 (12.6–14.0) | 14.0 (13.3–17.0) | 8.3 (7.7–NA) | 15.5 (15.2–16.0) | 11.2 (11.0–12.1) | NA |
| Number of deaths throughout follow-up (%) | 652 (92) | 162 (89) | 53 (84) | 98 (93) | 107 (93) | 144 (94) | 88 (100) |
| Number of deaths within 5 years (%) | 587 (83) | 155 (85) | 48 (76) | 87 (83) | 82 (71) | 130 (84) | 85 (97) |
| Probability of survival at 1 year (%, 95% CI) | 44 (41–48) | 48 (41–55) | 44 (34–59) | 44 (35–54) | 60 (52–70) | 36 (29–44) | 27 (19–38) |
| Probability of survival at 3 years (%, 95% CI) | 22 (19–25) | 20 (15–27) | 28 (19–42) | 20 (14–29) | 34 (26–44) | 19 (14–27) | 7 (3–15) |
| Probability of survival at 5 years (%, 95% CI) | 17 (14–20) | 15 (11–22) | 22 (13–35) | 17 (11–26) | 28 (21–37) | 16 (11–23) | 2 (0.6–9) |
IQR: interquartile range. NA: unable to estimate because of too many events.
a
The median survival time was estimated using the Kaplan–Meier method, defining alive or loss to follow-up as the event and treating death as censoring. In the SCHS cohort, the median follow-up time could not be calculated because all participants died by the end of follow-up.